Alaunos Therapeutics, Inc. — Director's Dealing 2021

Mar 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ZIOPHARM ONCOLOGY INC (ZIOP)
CIK: 0001107421
Period of Report: 2021-03-04

Reporting Person: Buck Jill (EVP, GM Gene Therapy)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-04	Common Stock	A	31500	$0.00	Acquired	231016	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-04	Employee Stock Option (right to buy)	$4.31	A	236250	Acquired	2031-03-04	Common Stock (236250)	Direct

Footnotes

F1: 7,875 shares shall vest on each of 12/31/2021, 12/31/2022, 12/31/2023 and 12/31/2024.

F2: 1/16th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2020.